Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Subscribe To Our Newsletter & Stay Updated